Reducing racial disparities in liver cancer outcomes
Elimination Racial Disparities in Hepatocellular Carcinoma
This study is looking at how a special molecule called SATB2 inhibitor might help improve treatment for African Americans with liver cancer, by exploring how different factors like environment and genetics affect the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glax, LLC NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project ID | NIH-11061303 on NIH RePORTER |
What this research studies
This research focuses on addressing the higher rates of hepatocellular carcinoma (HCC) among African Americans by investigating a patented molecule known as SATB2 inhibitor. The study aims to understand how environmental, economic, and genetic factors contribute to the development and progression of HCC in this population. By utilizing advanced methodologies, including in vitro and in vivo testing, the research seeks to identify effective treatments that can improve survival rates for African American patients suffering from this disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American individuals diagnosed with hepatocellular carcinoma.
Not a fit: Patients who do not have hepatocellular carcinoma or are not of African American descent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for African American patients with liver cancer.
How similar studies have performed: Previous research has shown promise in addressing health disparities in cancer treatment, indicating that this approach could yield significant advancements.
Where this research is happening
Wilmington, United States
- Glax, LLC — Wilmington, United States (Active)
Researchers
- Principal investigator: Srivastava, Rakesh K. — Glax, LLC
- Study coordinator: Srivastava, Rakesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.